Bernstein downgraded Smith & Nephew to Market Perform from Outperform with a $37.50 price target Smith & Nephew’s stock has seen a strong rally in 2025 year-to-date based on solid revenue growth and an inflection in Orthopedic profitability, the firm notes. With consensus 2026 EPS now 10% higher than at the start of the year, coupled with a recent recovery in valuation, Bernstein is moving to the sidelines.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNN:
- Smith+Nephew to Host Capital Markets Days in December 2025
- Smith & Nephew Announces Share Capital Update for September 2025
- Smith+Nephew CFO Relocates to US to Strengthen Market Focus
- Smith & Nephew’s Growth Potential and Strategic Initiatives Reinforce Buy Rating
- Smith & Nephew price target raised to 1,445 GBp at Rothschild & Co Redburn